BioAtla
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 65
- Market Cap
- $86.5M
- Website
- http://www.bioatla.com
- Introduction
BioAtla, Inc. engages in the development of novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its CAB portfolio include MABs & ADCS, BA3011, and BA3021. The company was founded by Jay M. Short and Carolyn Anderson in March 2007 and is headquartered in San Diego, CA.
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 168
- Registration Number
- NCT05808634
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸University of Illinois, Chicago, Illinois, United States
🇺🇸The Christ Hospital Cancer Center, Cincinnati, Ohio, United States
A Phase 2 Open Label Study of BA3021 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2023-09-29
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05271604
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Christiana Care Helen Graham Cancer Center, Newark, Delaware, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody (Currently Enrolling Patients With Nonsquamous or Recurrent NSCLC (Type IIB, IIIA, IV)
- Conditions
- Interventions
- First Posted Date
- 2022-01-06
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 320
- Registration Number
- NCT05180799
- Locations
- 🇺🇸
Northwest Cancer Centers, Dyer, Indiana, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
CAB-AXL-ADC Safety and Efficacy Study in Adults with NSCLC
- Conditions
- Interventions
- First Posted Date
- 2020-12-23
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04681131
- Locations
- 🇺🇸
City of Hope - Duarte, Duarte, California, United States
🇺🇸University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Irvine, California, United States
🇺🇸California Research Institute, Los angeles, California, United States
CAB-ROR2-ADC Safety and Efficacy Study in Patients with TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)
- Conditions
- Interventions
- First Posted Date
- 2018-04-20
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 420
- Registration Number
- NCT03504488
- Locations
- 🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸City of Hope - Duarte, Duarte, California, United States
🇺🇸University of California, San Diego (UCSD) - Moores Cancer Center, La Jolla, California, United States
CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma
- Conditions
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- BioAtla, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT03425279
- Locations
- 🇺🇸
Tower Hematology Oncology Medical Group, Los Angeles, California, United States
🇺🇸Precision NextGen Oncology, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States